News & Press
BioMotiv News & Press
Aro Biotherapeutics is a biotechnology company developing Centyrins, an innovative, next-generation protein drug platform that can be used for targeted drug delivery or as antibody-like therapeutics. The company has been launched with support from Johnson & Johnson Innovation and BioMotiv.
Click to view related media coverage.
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2019 Harrington Scholar-Innovator Award recipients. The projects supported by the awards include new therapeutics to treat metabolic disorders, autoimmune disorders and cancer, and new approaches to eradicate parasitic diseases in developing countries.
PharmaLex Group, one of the largest and most successful specialist providers of Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology and Risk Management worldwide, has entered into a preferred partnership with BioMotiv, a mission-driven accelerator that advances breakthrough discoveries from research institutions into therapeutics for patients.
Sujana Biotech, a biotechnology company developing novel therapeutics to prevent inflammatory and vascular disorders, today announced new funding from the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke at the National Institutes for Health.
BioMotiv and Cure Network Dolby Acceleration Partners (CNDAP) have entered into an agreement to develop small molecules that could provide new treatment options for patients with neurological disorders, such as Dravet syndrome, other epilepsies, and Alzheimer’s disease.
Koutif Therapeutics today announced that KT-1002, which has been selected as its lead compound, has reached clinical candidate status for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s Disease, after successfully completing IND-enabling studies.
OptiKira, LLC, a privately-held biotechnology startup developing drugs that inhibit the unfolded protein response (UPR) with applications in a variety of diseases, including retinitis pigmentosa, type I diabetes, idiopathic pulmonary fibrosis (IPF), amyotrophic lateral sclerosis (ALS), and immuno-oncology announced today that it achieved a significant proof-of-principle milestone.
Margaret Brimble, CNZM, FRSNZ, PhD, co-scientific founder of SapVax and Distinguished Professor & Director, Medicinal Chemistry at The University of Auckland, has been awarded the 2018 George and Christine Sosnovsky Award in Cancer Therapy from the Royal Society of Chemistry (United Kingdom).
On Wednesday, April 25, BioMotiv colleagues and friends gathered to celebrate the opening of a new Philadelphia office located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures.
“Emerging drug discovery alliance models” discusses the current environment for early-stage drug discovery and development, highlights challenges to success, and suggests the need for allied partnerships in the drug development sphere using BioMotiv as one such model.